It regulates HLA class I and induces apoptosis in HER2/neu beneficial tumor cell lines. Int J Cancer. 2004, 77th 108:71 Christianson TA, Doherty JK, Lin YJ, Ramsey EE, Holmes R, Keenan EJ, et al. NH 2-terminally truncated HER-2/neu SA: Vergie no partnership with extracellular Ren Ren Cathedral and prognostic components for breast cancer. buy PIK-294 Cancer Res 1998, 58:5123 5129th Citri A, Alroy I, Lavi S, Rubin C, Xu W, Grammatikakis N, et al. Drug-induced ubiquitination and degradation erbB receptor tyrosine kinases. Implications to the treatment method of cancer EMBO J 2002, 21:2407 2417th Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity t t towards tumor targets. Nature Medicine. 2000, six:443 446th Colomer R, Lupu R, Bacus SS, Engelmann EP.
erbB 2 antisense oligonucleotides inhibit proliferation of breast cancer cells with erbB oncogene amplification rkungsfaktorsteuerung second Br J Cancer. 1994, 70:819 825th Cooley S, Burns LJ, Repka T, Miller JS. Normal killer T-cell cytotoxicity ENMD-2076 t Of breast cancer targets is by two unique mechanisms surveilance old K Entire body surveilance-Dependent cytotoxicity t Re Improves cellular communication LFA towards t 3 and HER2/neu. Exp Hematol. 1999, Oncogene 1541 27:1533. Page Moasser 14th Writer manuscript 6th, April 2011 PMC. Cortes JE, Baselga J, Kellokumpu Lehtinen, Pirkko Liisa, Bianchi G, Cameron D, Miles D, Salvagni S, Wardley A, Goeminne J, Gianni L. open, randomized phase II research of pertuzumab in metastatic breast cancer with very low expression HER2. Proc Amer Soc Clin Onc.
2005, 23 M # 3068th Cuello, SA Ettenberg, AS Clark, Keane MM, Posner RH, Nau MM, et al. Downregulation in the erbB receptor two with trastuzumab enhanced tumor necrosis factor-related apoptosis by ligand exchange apoptosisinducing breast and ovarian cancer cells overexpressing erbB two lines mediation. Cancer Res 2001, 61:4892 4900th LC, R Cozzolino, Carpentieri A, Pucci Laccetti P P, D, G. Alessio biological properties of human Antique RPers towards ErbB2 compact. Carcinogenesis. 2005, 26:1890 1895th Deshane J, J Grim, Loechel S, Siegal GP, Alvarez RD, Curiel DT. Re intracellular Ren outdated K Entire body towards erbB two mediator specifically goal to reduce tumor cells by apoptosis. Cancer Gene Ther. 1996, 98th three:89 Dier Meier S, Horvath G, Clarke R Knuchel Hofstaedter F, Szollosi J, Brockhoff G.
Epidermal growth factor receptor modulating coexpression requests Herceptin. Sensitivity in breast cancer overexpress HER2/neu targeted erbB receptor interaction and activation Exp Cell Res 2005, 304:604 619th Discafani CM, Carroll ML, Floyd MB Jr, Hollander IJ, Husain Z, Johnson BD, et al. Irreversible inhibition on the kinase of your epidermal growth aspect receptor with tyrosine in vivo activity of t T 6 of N quinazolinyl] butynamide 2nd Biochem Pharmacol. 1999, 57:917 925th Drebin JA, Hyperlink VC, Greene MI. Rpern monoclonal NEN Cathedral with various neu oncogene-encoded p185 molecule exert synergistic anti-tumor impact in vivo. Oncogene. 1988, 2:273 277th Drebin JA, Hyperlink VC, Stern DF, Weinberg RA, Greene MI. Open modulating one particular oncogene protein merchandise and reversion of transformed Notyps Ph K Monoclonal body. Cell. 1985, 41:697 706th Egeblad M, Mortensen OH Jaattela M. ErbB2 signaling and induces ErbB1 enhanced cutting insert, reduction of epithelial cells independently Ngig Morph surveilance-Dependent ERK